Myhibbin is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 16, 2039. Details of Myhibbin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12097285 | Mycophenolate oral suspension |
Aug, 2039
(14 years from now) | Active |
| US12097284 | Mycophenolate oral suspension |
Aug, 2039
(14 years from now) | Active |
| US11931455 | Pharmaceutical suspension for oral dosage |
Aug, 2039
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Myhibbin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Myhibbin's family patents as well as insights into ongoing legal events on those patents.
Myhibbin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Myhibbin's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 16, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Myhibbin Generic API suppliers:
Mycophenolate Mofetil is the generic name for the brand Myhibbin. 21 different companies have already filed for the generic of Myhibbin, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Myhibbin's generic
Alternative Brands for Myhibbin
There are several other brand drugs in the same treatment category and using the same active ingredient (Mycophenolate Mofetil) as Myhibbin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Veloxis Pharms Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Mycophenolate Mofetil. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Roche Palo |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Mycophenolate Mofetil, Myhibbin's active ingredient. Check the complete list of approved generic manufacturers for Myhibbin
About Myhibbin
Myhibbin is a drug owned by Azurity Pharmaceuticals Inc. Myhibbin uses Mycophenolate Mofetil as an active ingredient. Myhibbin was launched by Azurity in 2024.
Approval Date:
Myhibbin was approved by FDA for market use on 01 May, 2024.
Active Ingredient:
Myhibbin uses Mycophenolate Mofetil as the active ingredient. Check out other Drugs and Companies using Mycophenolate Mofetil ingredient
Dosage:
Myhibbin is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG/ML | SUSPENSION | Prescription | ORAL |